Literature DB >> 18393108

Cetilistat, a new lipase inhibitor for the treatment of obesity.

Raj Padwal1.   

Abstract

Alizyme plc, in collaboration with Takeda Pharmaceutical Co Ltd in Japan, is developing cetilistat, an oral non-absorbed synthetic lipase inhibitor, derived from Alizyme's pancreatic lipase inhibitor research program, for the potential treatment of obesity in patients with or without diabetes. It is also under investigation for the potential management of type 2 diabetes. Several phase II clinical trials for obesity have been completed. Phase III trials were in preparation at the time of publication.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18393108

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  6 in total

Review 1.  Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.

Authors:  Marcelo O Dietrich; Tamas L Horvath
Journal:  Nat Rev Drug Discov       Date:  2012-08-03       Impact factor: 84.694

Review 2.  Obesity pharmacotherapy: current perspectives and future directions.

Authors:  Monika Misra
Journal:  Curr Cardiol Rev       Date:  2013-02-01

3.  Effects of Totum-63 on glucose homeostasis and postprandial glycemia: a translational study.

Authors:  Vivien Chavanelle; Yolanda F Otero; Florian Le Joubioux; Doriane Ripoche; Maxime Bargetto; Aurore Vluggens; Christophe Montaurier; Gisèle Pickering; Gilles Ducheix; Claude Dubray; Christian Dualé; Sylvia Boulliau; Nicolas Macian; Geoffroy Marceau; Vincent Sapin; Frédéric Dutheil; Bruno Guigas; Thierry Maugard; Nathalie Boisseau; Murielle Cazaubiel; Sébastien L Peltier; Pascal Sirvent
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-05-03       Impact factor: 5.900

4.  SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.

Authors:  Hiroaki Yashiro; Kenichi Hamagami; Hideyuki Hiyoshi; Jun Sugama; Kazue Tsuchimori; Fuminari Yamaguchi; Yusuke Moritoh; Minoru Sasaki; Tsuyoshi Maekawa; Yukio Yamada; Masanori Watanabe
Journal:  Diabetes Obes Metab       Date:  2019-07-02       Impact factor: 6.577

5.  Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.

Authors:  Shuofeng Yuan; Jasper F W Chan; Kenn K H Chik; Chris C Y Chan; Jessica O L Tsang; Ronghui Liang; Jianli Cao; Kaiming Tang; Lin-Lei Chen; Kun Wen; Jian-Piao Cai; Zi-Wei Ye; Gang Lu; Hin Chu; Dong-Yan Jin; Kwok-Yung Yuen
Journal:  Pharmacol Res       Date:  2020-05-28       Impact factor: 7.658

6.  Design and syntheses of 7-nitro-2-aryl-4H-benzo[d][1,3]oxazin-4-ones as potent anticancer and antioxidant agents.

Authors:  Ayesha Bari; Zulfiqar Ali Khan; Sohail Anjum Shahzad; Syed Ali Raza Naqvi; Shakeel Ahmad Khan; Hira Amjad; Ahsan Iqbal; Muhammad Yar
Journal:  J Mol Struct       Date:  2020-04-13       Impact factor: 3.196
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.